Ernexa Therapeutics Inc. Cash Flow Statement
ERNA|13 years of annual SEC 10-K data (FY2011-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 13 fiscal years. All figures from audited SEC 10-K filings.
Ernexa Therapeutics Inc. used $16M in operating cash flow and negative free cash flow of $16M in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -8.07 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -$44.5M | -$21.7M | -$24.6M | -$2.0M | -$259.0K | -$1.1M | -$2.9M | -$7.2M | -$5.0M | -$1.1M | -$995.0K | -$3.4M | -$400.0K |
| Depreciation & Amortization | $139.0K | $84.0K | $161.0K | $360.0K | $2.8M | $2.3M | $2.9M | $3.1M | $2.7M | $2.8M | $2.9M | $3.3M | $3.2M |
| Operating Cash Flow | -$15.8M | -$20.4M | -$21.0M | $2.7M | $1.4M | $549.0K | $23.0K | -$4.2M | -$6.4M | $1.7M | $2.2M | $574.0K | $2.8M |
| Capital Expenditures | $369.0K | $19.0K | $297.0K | $966.0K | $648.0K | $728.0K | $427.0K | $991.0K | $835.0K | $1.1M | $1.2M | $1.6M | $1.3M |
| Free Cash Flow | -$16.2M | -$20.4M | -$21.3M | $1.8M | $717.0K | -$179.0K | -$404.0K | -$5.2M | -$7.2M | $632.0K | $930.0K | -$1.0M | $1.5M |
| FCF Margin | -2784.4% | -30039.7% | - | 9.0% | 3.1% | -0.8% | -1.8% | -21.1% | -27.7% | 2.7% | 3.9% | -4.3% | 6.0% |